Adaptive translational reprogramming of metabolism limits the response to targeted therapy in BRAF(V600) melanoma

Despite the success of therapies targeting oncogenes in cancer, clinical outcomes are limited by residual disease that ultimately results in relapse. This residual disease is often characterized by non-genetic adaptive resistance, that in melanoma is characterised by altered metabolism. Here, we exa...

Descripción completa

Detalles Bibliográficos
Autores principales: Smith, Lorey K., Parmenter, Tiffany, Kleinschmidt, Margarete, Kusnadi, Eric P., Kang, Jian, Martin, Claire A., Lau, Peter, Patel, Riyaben, Lorent, Julie, Papadopoli, David, Trigos, Anna, Ward, Teresa, Rao, Aparna D., Lelliott, Emily J., Sheppard, Karen E., Goode, David, Hicks, Rodney J., Tiganis, Tony, Simpson, Kaylene J., Larsson, Ola, Blythe, Benjamin, Cullinane, Carleen, Wickramasinghe, Vihandha O., Pearson, Richard B., McArthur, Grant A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8888590/
https://www.ncbi.nlm.nih.gov/pubmed/35232962
http://dx.doi.org/10.1038/s41467-022-28705-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8888590/
https://www.ncbi.nlm.nih.gov/pubmed/35232962
http://dx.doi.org/10.1038/s41467-022-28705-x

Ejemplares similares